435 related articles for article (PubMed ID: 26427800)
1. A cell-targeted chemotherapeutic nanomedicine strategy for oral squamous cell carcinoma therapy.
Wang ZQ; Liu K; Huo ZJ; Li XC; Wang M; Liu P; Pang B; Wang SJ
J Nanobiotechnology; 2015 Oct; 13():63. PubMed ID: 26427800
[TBL] [Abstract][Full Text] [Related]
2. Development of α-tocopherol surface-modified targeted delivery of 5-fluorouracil-loaded poly-D, L-lactic-co-glycolic acid nanoparticles against oral squamous cell carcinoma.
Srivastava S; Gupta S; Mohammad S; Ahmad I
J Cancer Res Ther; 2019; 15(3):480-490. PubMed ID: 31169208
[TBL] [Abstract][Full Text] [Related]
3. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery.
Parveen S; Sahoo SK
Eur J Pharmacol; 2011 Nov; 670(2-3):372-83. PubMed ID: 21951969
[TBL] [Abstract][Full Text] [Related]
4. Translocator protein ligand-PLGA conjugated nanoparticles for 5-fluorouracil delivery to glioma cancer cells.
Laquintana V; Denora N; Lopalco A; Lopedota A; Cutrignelli A; Lasorsa FM; Agostino G; Franco M
Mol Pharm; 2014 Mar; 11(3):859-71. PubMed ID: 24410438
[TBL] [Abstract][Full Text] [Related]
5. Poly(lactide)-vitamin E derivative/montmorillonite nanoparticle formulations for the oral delivery of Docetaxel.
Feng SS; Mei L; Anitha P; Gan CW; Zhou W
Biomaterials; 2009 Jul; 30(19):3297-306. PubMed ID: 19299012
[TBL] [Abstract][Full Text] [Related]
6. Hyaluronic acid-decorated poly(lactic-co-glycolic acid) nanoparticles for combined delivery of docetaxel and tanespimycin.
Pradhan R; Ramasamy T; Choi JY; Kim JH; Poudel BK; Tak JW; Nukolova N; Choi HG; Yong CS; Kim JO
Carbohydr Polym; 2015 Jun; 123():313-23. PubMed ID: 25843864
[TBL] [Abstract][Full Text] [Related]
7. Targeted and controlled drug delivery system loading artersunate for effective chemotherapy on CD44 overexpressing cancer cells.
Tran TH; Nguyen TD; Van Nguyen H; Nguyen HT; Kim JO; Yong CS; Nguyen CN
Arch Pharm Res; 2016 May; 39(5):687-94. PubMed ID: 27015824
[TBL] [Abstract][Full Text] [Related]
8. Targeted hepatocellular carcinoma therapy: transferrin modified, self-assembled polymeric nanomedicine for co-delivery of cisplatin and doxorubicin.
Zhang X; Li J; Yan M
Drug Dev Ind Pharm; 2016 Oct; 42(10):1590-9. PubMed ID: 26942448
[TBL] [Abstract][Full Text] [Related]
9. AS1411 aptamer tagged PLGA-lecithin-PEG nanoparticles for tumor cell targeting and drug delivery.
Aravind A; Jeyamohan P; Nair R; Veeranarayanan S; Nagaoka Y; Yoshida Y; Maekawa T; Kumar DS
Biotechnol Bioeng; 2012 Nov; 109(11):2920-31. PubMed ID: 22615073
[TBL] [Abstract][Full Text] [Related]
10. Improved therapeutic effect of folate-decorated PLGA-PEG nanoparticles for endometrial carcinoma.
Liang C; Yang Y; Ling Y; Huang Y; Li T; Li X
Bioorg Med Chem; 2011 Jul; 19(13):4057-66. PubMed ID: 21641806
[TBL] [Abstract][Full Text] [Related]
11. Multifunctional poly(D,L-lactide-co-glycolide)/montmorillonite (PLGA/MMT) nanoparticles decorated by Trastuzumab for targeted chemotherapy of breast cancer.
Sun B; Ranganathan B; Feng SS
Biomaterials; 2008 Feb; 29(4):475-86. PubMed ID: 17953985
[TBL] [Abstract][Full Text] [Related]
12. Biodegradable nanoparticles sequentially decorated with Polyethyleneimine and Hyaluronan for the targeted delivery of docetaxel to airway cancer cells.
Maiolino S; Russo A; Pagliara V; Conte C; Ungaro F; Russo G; Quaglia F
J Nanobiotechnology; 2015 Apr; 13():29. PubMed ID: 25888948
[TBL] [Abstract][Full Text] [Related]
13. Low-molecular-weight protamine-modified PLGA nanoparticles for overcoming drug-resistant breast cancer.
Wang H; Zhao Y; Wang H; Gong J; He H; Shin MC; Yang VC; Huang Y
J Control Release; 2014 Oct; 192():47-56. PubMed ID: 25003794
[TBL] [Abstract][Full Text] [Related]
14. Fabrication of curcumin encapsulated PLGA nanoparticles for improved therapeutic effects in metastatic cancer cells.
Yallapu MM; Gupta BK; Jaggi M; Chauhan SC
J Colloid Interface Sci; 2010 Nov; 351(1):19-29. PubMed ID: 20627257
[TBL] [Abstract][Full Text] [Related]
15. Electrohydrodynamic fabrication of core-shell PLGA nanoparticles with controlled release of cisplatin for enhanced cancer treatment.
Reardon PJ; Parhizkar M; Harker AH; Browning RJ; Vassileva V; Stride E; Pedley RB; Edirisinghe M; Knowles JC
Int J Nanomedicine; 2017; 12():3913-3926. PubMed ID: 28579777
[TBL] [Abstract][Full Text] [Related]
16. Poly aspartic acid peptide-linked PLGA based nanoscale particles: potential for bone-targeting drug delivery applications.
Jiang T; Yu X; Carbone EJ; Nelson C; Kan HM; Lo KW
Int J Pharm; 2014 Nov; 475(1-2):547-57. PubMed ID: 25194353
[TBL] [Abstract][Full Text] [Related]
17. Transferrin surface-modified PLGA nanoparticles-mediated delivery of a proteasome inhibitor to human pancreatic cancer cells.
Frasco MF; Almeida GM; Santos-Silva F; Pereira Mdo C; Coelho MA
J Biomed Mater Res A; 2015 Apr; 103(4):1476-84. PubMed ID: 25046528
[TBL] [Abstract][Full Text] [Related]
18. Folate-decorated anticancer drug and magnetic nanoparticles encapsulated polymeric carrier for liver cancer therapeutics.
Li YJ; Dong M; Kong FM; Zhou JP
Int J Pharm; 2015 Jul; 489(1-2):83-90. PubMed ID: 25888801
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and in vitro studies of PLGA-DTX nanoconjugate as potential drug delivery vehicle for oral cancer.
Gupta P; Singh M; Kumar R; Belz J; Shanker R; Dwivedi PD; Sridhar S; Singh SP
Int J Nanomedicine; 2018; 13(T-NANO 2014 Abstracts):67-69. PubMed ID: 29593398
[TBL] [Abstract][Full Text] [Related]
20. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
